Clinical Trial 55037

Berlin, NJ 08009


Summary:

A phase III, multicentre, randomised, double-blind,controlled study to investigate the efficacy, safety,and tolerability of two administrations of COMP360 in participants with treatment-resistant depression


Qualified Participants Must:

• Be at least 18 years old
• Have been diagnosed with major depression (single or recurrent episodes)
• if a single episode, it should be a duration between 3 months and 2 years
• Are experiencing treatment-resistant depression, defined as failing 2, 3 or 4 pharmacological treatments for their current episode of depression
• Other criteria will need to be met to confirm a participant's eligibility for COMP 006 study


Qualified Participants May Receive:

Up to $1,225 for eligible participants


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.